ABSTRACT During the amino acid sequence determination of crotalase (EC 3.4.21.30), the. thrombin-like enzyme from the venom of Crotals mantes-(eastern diamondback rattlesnake), we found that, in addition to the expected structural homologywith bovine thrombin (EC 3.4.21.5), there was even greater homology with porcine pancreatic kallikrein (EC 3.4.21.8). In exploring further the similarities between crotalase and kallikrein, several striking observations were made. First, crotalase was rapidly and specifically inhibited by the tripeptide affinity labeling derivative prolylphenylalanylarginine chloromethyl ketone, which is known to be a specific inhibitor of kallikrein. Second, NaDodSO4 acrylamide gel electrophoresis revealed that crotalase cleaves the plasma kallikrein-susceptible bonds. in human high molecular weight kininogen, producing an intermediate with procoagulant activity. Crotalase-catalyzed cleavage of high molecular weight kininogen also liberates kinin as evidenced by rat blood pressure bioassay. Finally,. crotalase exhibits substrate specificity not only for the thrombin chromogenic substrate S-2238 but also for the kallikrein substrates S-2302 and S-2266. Interestingly, one of the other reactions catalyzed by, plasma kallikrein, the activation of plasminogen, was not one of the activities exhibited-by crotalase.
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Crotalase (EC 3.4.21.30), the thrombin-like enzyme from the venom of Crotalus adamanteus (eastern diamondback rattlesnake) has been purified to homogeneity (1) (2) (3) (4) . Physicochemical characterization of crotalase indicated that it contains a single polypeptide chain with a molecular weight of 33,000 (1) . Although analysis for carbohydrate indicated that the enzyme is a sialoglycoprotein, removal of the sialic acid does not appear to alter its enzymatic activity (2) . Crotalase clots fibrinogen and plasma anticoagulated with EDTA or heparin (5) . In contrast to thrombin (EC 3.4.21.5), crotalase cleaves only fibrinopeptide A from fibrinogen (6) and it does not activate factor XIII (4) . There are also other subtle differences in specificity between these two enzymes (4, 7) .
The enzymatic properties of crotalase have been investigated, and it has been found that the enzyme exhibits esterase activity on small, basic amino acid esters (1) . Both coagulant and esterase activities are inhibited-rapidly and simultaneously by diisopropyl fluorophosphate. These findings are consistent with crotalase being a member of the serine protease family (1, 3, 4) . Interestingly, the chloromethyl ketone ofN-aAtosyl-L-lysine also inhibits both esterase and coagulant activities but only partially and with a very slow reaction rate.
During recent investigations aimed at elucidating the primary structure of crotalase (8, 9) , it became evident that there was significant homology between the sequence ofcrotalase (9) and the known primary structure of thrombin (10) . Of more interest, however, was the even greater degree of homology between crotalase (9) and glandular kallikrein (EC 3.4.21.8) (11) . Although these findings were unexpected; there are several reports in the literature showing that snake venoms have kininreleasing (kallikrein-like) activity. Mitchell and Reichert in the late 1800s reported a hypotensive effect in dogs after envenomation by members of the Crotalidae family (12) . More recently, Russell has shown that several Crotalidae venoms possess. kinin-releasing activity (13) .
In view ofthe reports ofkinin-releasing activity in snake venoms and our finding of structural homology between crotalase and kallikrein, we initiated a series of experiments to further characterize the relationship between these enzymes. It is the purpose of this report to detail our studies on the remarkable similarities we have identified between crotalase and kallikrein.
MATERIALS AND METHODS
Crotalase Preparation. Crotalase was prepared from eastern diamondback rattlesnake venom by a previously described procedure (2).. Lyophilized venom was obtained from the Miami Serpentarium (Miami, FL).
Synthesis of Peptide Chloromethyl Ketones. Tripeptide chloromethyl ketones with carboxyl-terminal arginine were prepared by coupling NH2-blocked peptides to HArg(NO2)CH2Cl (NO2 being in the co position), using the mixed anhydride procedure (14) ; Final products were obtained by removing protective groups with. anhydrous HF. The synthesis of Pro-Phe-ArgCH2Cl was described previously (14) , as was the synthesis of Ac-Pro-Phe-ArgCH2C1 (15 Clotting activity of crotalase was determined by using a buffered solution ofhuman fibrinogen (10 mg/ml) as described (3) . Activity is expressed in National Institutes of Health equivalent thrombin clotting units.
Kinetic Analysis of Crotalase Inhibition by Peptide Chloromethyl Ketones. Inactivation ofcrotalase was studied at 250C in 1.00 ml of50 mM piperazine-N,N'-bis(2-ethanesulfonic acid) buffer (pH 7.0), containing 0.20 M NaCl and the arginine chloromethyl ketone. The inactivation reaction was initiated by the addition of5 A.l of crotalase (8.5 PLM), and 100-tlI aliquots were removed at 3-min intervals and assayed'for residual thioesterase activity by using Z-Lys-SBzl as described above. The apparent pseudo-first-order rate constant, kapp, for the inactivation reaction was determined from the slope of the semilogarithmic plot of esterase activity versus time. Values of1I, the reversible binding constant, and k2, the first-order rate constant for the alkylation reaction, were determined by the equation described by Kitz and' Wilson (17):
At least four values of ka pwere determined at different concentrations of the affinity libel, I, and kinetic constants were determined from double-reciprocal plots of kapp versus I after determining the best line by the method of least squares.
Affinity Labeling of Crotalase by rH]Ac-Pro-Phe-ArgCH2Cl.
[3H]Ac-Pro-Phe-ArgCH2Cl (10 ,ul of a 10 mM solution) was added to 0.023 ,umol of crotalase in 0.45 ml of 40 mM Tris HCl buffer (pH 7.4) containing 0.1 M NaCl. After 95 min at 25°C, no thioesterase activity could be detected. The solution was applied to a 1.3 X 61.5 cm column of Sephadex G-25 to remove excess radiolabeled peptide chloromethyl ketone. The column was eluted with 0.10 M Tris HCl buffer (pH 7.4), and 1.0-ml fractions were collected. Protein and radioactivity were eluted in fractions 18-21 and radioactivity was also eluted in fractions 30-51. The radioactivities of aliquots of the fractions were measured in Aquasol, using the LS 233 scintillation counter.
Sequence Analysis of Crotalase. Portions of the amino acid sequence have been reported separately (9) .
Reaction of Crotalase with High Molecular Weight Kininogen (HMWK). HMWK was prepared as described (18) . The preparations used in these experiments had an activity of about 8 units/ml with a specific activity of 15 units/mg. There was no detectable factor XI, factor XII, or Fletcher factor activity. Human plasma kallikrein, prepared as described (19) , had a Fletcher factor activity of about 0.04 unit/ml at the time of use. It was purified about 80-fold over normal plasma and had no factor XI, factor XII, or HMWK activity. Crotalase was purified to homogeneity and had a specific activity of 470 National Institutes of Health equivalent thrombin clotting units/mg. was added to each reaction mixture and the contents were heated at 37°C for 1 hr. Each reduced mixture was then subjected to NaDodSOJacrylamide gel electrophoresis on 10% slab gels (140 x 95 x 0.75 mm) essentially as described by Laemmli (20) . Gels were run at 13 mA for 4 hr with tap water cooling, and after the run gels were stained with Coomassie brilliant blue. Proteins of known molecular weight were run as standards. Gels were scanned with a Gilford spectrophotometer and quantitated with an integrating recorder.
Crotalase-Catalyzed Kinin Release from HMWK. HMWK (10 pkl of the preparation containing about 8 units/ml in 0.05 M Tes/0. 10 M NaCl pH 7.35 buffer) was incubated with either 20 .ul ofcrotalase (80 units/ml in 0.04 M Tris HCl/0. 10 M NaCl, pH 7.35) or 20 Al of Tes/NaCl buffer for 3 hr at 370C and an additional 18 hr at 20'C. The reaction was stopped by the addition of 15 A.l of 10% 2-mercaptoethanol in 6% NaDodSO4 to each tube followed by incubation for 1 hr at 370C. A buffer control and a crotalase control (in which the Tes/NaCl buffer was substituted for HMWK) were similarly treated. After addition of 2-mercaptoethanol/NaDodSO4, incubation mixtures containingcrotalase-treated HMWK, HMWK alone, crotalase control, and buffer control were lyophilized and the residue was dissolved in 100 jul ofphysiological saline. Bioassays ofbradykinin release were carried out essentially as described (15) . Samples were injected separately into the right carotid artery of260-g Fisher female rats anesthetized with urethane (1.6 g per kg). All injections were in a final volume of 100 pul of physiological saline, and samples were washed in with an additional 100 ,u of saline. Rats were tested before the experimental protocols by injecting 20 ng of bradykinin (Sigma) two to five times to establish sensitivity. Blood pressure was monitored by a Grass polygraph connected to a Statham pressure transducer that was inserted through a cannula in the left femoral artery.
Hydrolysis of Chromogenic Substrates by Crotalase. A 0.1-ml solution of the chromogenic substrate (S-2238, S-2302, or S-2266, from Kabi Diagnostica, Stockholm) in distilled water was placed in a quartz semimicro cuvette, followed by 0.86 ml of 50 mM Tris HCl/0.05 M NaCl at pH 7.35 (or pH 8.0 for S-2302). Substrate concentrations varied between 5 and 800 ,tM. Reaction mixtures were preincubated at 37°C for 5 min in the jacketed sample compartment of a Beckman model 25 spectrophotometer with a recorder attachment. The reaction was started by adding 40 ,ul of crotalase solution containing 8 National Institutes of Health clotting units/ml and the absorbance at 405 nm was followed for 5 min against a blank containing buffer and chromogenic substrate. The spontaneous hydrolysis rate was subtracted from the rate ofenzyme-catalyzed hydrolysis.
Crotalase Action on Plasminogen. Activation of human plasminogen by crotalase was determined by the azocaseinolytic activity ofthe plasmin generated as described (21) . NaDodSO4/ acrylamide gel electrophoretic analysis (22) was also carried out on the activation samples (after reduction of the disulfide *bridges with 2-mercaptoethanol) to detect the formation of the polypeptide chains of plasmin (21) . In control experiments plasminogen was activated by streptokinase.
RESULTS
Inhibition of Crotalase by Peptide Chloromethyl Ketones. Our earlier studies (1) showed that crotalase was inhibited rather poorly by the chloromethyl ketone of tosyl-L-lysine. Re- cently, however, we found that crotalase is inhibited quite rapidly by Pro-Phe-ArgCH2Cl. Pro-Phe-Arg is the tripeptide sequence at the carboxy terminus of bradykinin that is cleaved by kallikrein, and Pro-Phe-ArgCH2Cl is an effective and specific inhibitor of plasma kallikrein (14) . As shown in Fig. 1 , the time for 50% inactivation of crotalase by 5 .tM Pro-Phe-ArgCH2Cl is 3.8 min. From the reciprocal plot(17) of the apparent pseudofirst-order rate constant (k ) against Pro-Phe-ArgCH2Cl concentration (I), the affinity of crotalase for the chloromethyl ketone inhibitor (14) was determined as 11 ,.M, whereas the rate constant for the irreversible step of the affinity labeling reaction, k2, was found to be 0.57 min-. (Inset) Double-reciprocal plot of kap versus inhibitor concentration (I), which was used to determine the reversible binding constant, Ki, and the first-order rate constant, k2, for the alkylation reaction of ProPhe-ArgCH2Cl with crotalase. Four values of k were determined at different concentrations of Pro-Phe-ArgCH2CI. iThe slope and intercept were used to calculate Ki and k2 from the equation of Kitz and Wilson (17) given in the text. Ki = 10.8 ,uM; k2 = 0.567 min'1.
When a 4-fold molar excess of [3H]Ac-Pro-Phe-ArgCH2Cl was used to affinity label crotalase, thioesterase activity was completely lost within 90 min. After removal of unreacted affinity labeling reagent by gel filtration on Sephadex G-25, aliquots were analyzed for radioactivity and protein concentration; there was stoichiometric incorporation of the affinity labeling reagent. NaDodSOJacrylamide gel electrophoresis (22) of the inhibited enzyme revealed exact correspondence ofthe position of the peak of tritium and ofthe single Coomassie blue staining band on the gel. During a separate reaction carried out in almost identical fashion (but with a 7-fold molar excess of inhibitor), aliquots were removed for assay of fibrinogen clotting activity and hydrolysis ofthe chromogenic substrates S-2238 and S-2302 (both at 1 mM). In the untreated sample crotalase clotting and chromogenic substrate activity remained unaltered during the 90-min course of the reaction. However, within 30 min after addition of the affinity labeling reagent to crotalase, both clotting activity and thrombin and kallikrein chromogenic substrate activities were completely inhibited. 1Ref. 24 , given as kapp/I.
Sequence of Crotalase. Sequence analysis of about 42% of the total structure ofecrotalase (113 out of about 267 residues) revealed 38% homology with porcine pancreatic kallikrein (9), which was more than with any of the other serine proteases of known sequence used for comparison. Trypsin, with 33% homology, and thrombin, with 29%, were the next closest (9) . These values are slightly different from those previously reported (9) due to the recent determination of an additional 16 residues of the sequence.
Crotalase Action on Human HMWK. Kallikrein action on HMWK has been shown to yield a molecule that is composed of a chain of about Mr 65,000 ("heavy" chain) and a smaller "light" chain variously reported as Mr 37,000 (25) , Mr 44,000 (26) , and Mr 54,000 (18) . Crotalase cleaved HMWK to yield heavy and light chains comparable to those formed by kallikrein (Fig. 2) . HMWK retained procoagulant activity after treatment with crotalase. Proc. Natl. Acad. Sci. USA 79 (1982) and crotalase-treated HMWK samples shown in Fig. 2 Samples 3, 4, 5 , and 6 were lyophilized and dissolved in 100 ,ul of physiological saline. All injections were in 100 ,u of saline and were followed by a 100-,ul saline wash. Data are given ± SD (three determinations).
arginine p-nitroanilide, S-2266, a substrate for glandular kallikrein (29) . When the kinetic data were plotted according to Lineweaver and Burk (30) to obtain Km and Vm., it was found ( Table 2 ) that crotalase exhibits significant activity with both kallikrein substrates, S-2302 and S-2266. These findings again illustrate the similarities between crotalase and kallikrein.
Lack of Activation of Human Plasminogen by Crotalase. Human plasma kallikrein weakly activates plasminogen (31) in a stoichiometric reaction (32) . Crotalase, on the other hand, failed to activate purified human plasminogen when they were incubated together for up to 60 min, even with equimolar and 4-fold molar excess of crotalase. However, in control experiments plasminogen was completely activated by streptokinase (500 units/mg of plasminogen) in 20 min. Activation was measured both by generation of azocaseinolytic activity and by NaDodSOJacrylamide gel electrophoresis. DISCUSSION Crotalase, the thrombin-like enzyme from eastern diamondback rattlesnake venom, has long been regarded as a serine protease of the trypsin class with both fibrinogen clotting activity and esterase activity on basic amino acid ester derivatives (1). Our preliminary findings that the enzyme exhibits remarkable similarities to kallikrein were surprising (9, 33, 34) .
In our original work (1) we found that crotalase exhibited very low reactivity with N-a-tosyl-L-lysine chloromethyl ketone. However, in the studies reported here we find that the enzyme reacts quite rapidly with a tripeptide chloromethyl ketone, ProPhe-ArgCH2Cl. This peptide chloromethyl ketone has the sequence of the carboxyl-terminal three residues in bradykinin and is an extremely effective and specific inhibitor of plasma kallikrein (14) . Interestingly, when several other chloromethyl ketones, which are effective and specific inhibitors ofthrombin, were tested for inhibitory activity with crotalase, they were much less effective than was Pro-Phe-ArgCH2Cl. Apparently (35) .
That the kallikrein-like activity of crotalase is not due to an impurity was shown by the following. First, the enzyme simultaneously loses fibrinogen clotting and chromogenic substrate activity during inhibition by Pro-Phe-ArgCH2Cl. Second, on the basis of the protein content of crotalase there is stoichiometric incorporation of [3H]Ac-Pro-Phe-ArgCH2Cl into the enzyme after 100% inactivation. Third, acrylamide gel electrophoresis by the method ofDavis (36) revealed that there is identical migration of native and [3H]Ac-Pro-Phe-ArgCH2Cl-inhibited crotalase (as shown by Coomassie blue staining) and of the peak of radioactivity of the tritiated chloromethyl ketone-inhibited enzyme and of the peak of clotting activity of native crotalase. Finally, sequence analysis shows a single amino-terminal residue for crotalase, ruling out the possibility of contaminant unless it has blocked amino-terminal residue. Studies to establish the amino acid sequence of crotalase have revealed a substantial similarity with kallikrein (9, 34) . Of the 113 residues of crotalase presently in sequence, there is a greater degree of homology (38%) with kallikrein than with any ofthe other serine proteases, including trypsin (33%), thrombin (29%), and factor X (23%). The sequence of kallikrein used for comparison is that from porcine pancreas (11); it is quite possible that there is an even greater degree of homology with plasma kallikrein. However, to date this structure remains unknown.
In addition to sequence homology and inhibition by the chloromethyl ketone inhibitor of plasma kallikrein, crotalase exhibits another activity characteristic of plasma kallikrein, cleavage of HMWK. Crotalase cleaves HMWK, producing cleavage products identical to those formed by kallikrein as shown by NaDodSOJacrylamide gel electrophoresis. Further, the fragments produced by crotalase have procoagulant activityjust like the kallikrein-derived fragments. Additionally, crotalase liberates kinin from HMWK, as shown by a drop in rat arterial blood pressure after infusion of crotalase-treated HMWK.
There have been several reports of kinin-releasing enzymes in snake venoms (13, 37) , including members ofthe rattlesnake family (13) . However, an association of this activity with the thrombin-like enzyme found in the venom has not been reported, to our knowledge. It is interesting that Viljoen et aL (37) reported on the identification of a serine esterase with kinin-releasing activity in the venom of Bitis gabonica. This enzyme may be the agent responsible for the marked transient blood pressure drop in dogs after infusion of the crude venom (38) . The kinin-releasing enzyme has a slightly different carbohydrate composition and is distinguishable both chromatographically and electrophoretically from the thrombin-like enzyme present in this venom. However, it has an almost identical amino acid composition to the thrombin-like enzyme (37) . In eastern diamondback rattlesnake venom, these two activities reside in a single enzyme; however, there may also be a separate kinin-releasing enzyme present in this venom.
Finally, in view of the fact that thrombin-like enzymes from both Agkistrodon rhodostoma, ancrod (39, 40) , and Bothrops atrox, batroxobin (41) , are being used clinically in Europe for the treatment of deep vein thrombosis, it will be of interest to determine if these enzymes also exhibit kallkrein-like activity. The finding of kallikrein-like activity should certainly not contraindicate the use of these enzymes. On the contrary, this activity (if present) may be acting to enhance the overall effectiveness of these clinical agents both by an improvement in the blood flow characteristics [Ehrly (42) has shown an improvement in the rheological properties ofblood after ancrod-induced fibrinogen depletion with a concomitant reduction in blood viscosity] and by the hypotensive or vasodilatory activity of the enzyme resulting in decreased peripheral resistance.
